stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Return on assets
Ligand Pharmaceuticals Incorporated's return on assets over the twelve months to 30 September 2026 was 2.77%, down 7.2 percentage points from fiscal 2025 (9.95%). Over the past ten years it has ranged from −3.24% (fiscal 2022) to 60.4% (fiscal 2015); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 9.95% | 10.42 |
| FY2024 | −0.47% | (7.20) |
| FY2023 | 6.73% | 9.97 |
| FY2022 | −3.24% | (7.54) |
| FY2021 | 4.30% | 4.51 |
| FY2020 | −0.21% | (45.88) |
| FY2019 | 45.7% | 30.83 |
| FY2018 | 14.8% | 12.87 |
| FY2017 | 1.97% | 2.27 |
| FY2016 | −0.30% | (60.69) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated | 2.77% |
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement